Nanotechnology As Potential Tool for siRNA Delivery in Parkinson's Disease

Author(s): Hernan Cortes, Sergio Alcala-Alcala, Arturo Avalos-Fuentes, Nestor Mendoza-Munoz, David Quintanar-Guerrero, Gerardo Leyva-Gomez*, Benjamin Floran*.

Journal Name: Current Drug Targets

Volume 18 , Issue 16 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Background: The lack of an outright treatment for Parkinson’s disease (PD) is a pivotal concern in medicine and has driven the search for novel alternatives for treating the disease. Among the proposed approaches, small interfering RNA (siRNA)-based therapy is attracting significant attention as a potential method for the treatment of PD; however, siRNAs delivery possesses potential drawbacks, such as reduced stability in blood circulation and low capacity for reaching the target site.

Objective: This review aims to explore siRNA-based approaches to PD and the latest advances for designing nanoparticles that effectively target siRNAs to the action site and that protect these against degradation in blood circulation.

Results: siRNA-based approaches provide an interesting option for designing new strategies for treating PD through the silencing of genes, whose abnormal expressions contribute to the pathophysiology of the disease; however, siRNA delivery to the brain is a key issue that remains unsolved to date. Current research efforts are focused on designing vectors that effectively transport and protect siRNAs. In this regard, nanoparticles are being developed as carriers for siRNAs with controlled delivery efficiency and low toxicity profiles, and these represent an alternative to common vectors.

Conclusion: Identification of putative gene targets for siRNA therapy of PD has set the pace for researching non-viral vectors; however, the technological aspects for tackling the challenge that siRNAs targeting to the brain represents are essentials. In this respect, the formulation of siRNAs in nanoparticles would avoid harmful side effects, such as immunogenic and oncogenic drawbacks.

Keywords: Parkinson's disease treatment, siRNA therapy, nanoparticle-based delivery of siRNA, siRNA drug targeting, blood-brain barrier, nanotechnology.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [1866 - 1879]
Pages: 14
DOI: 10.2174/1389450118666170321130003
Price: $58

Article Metrics

PDF: 26
PRC: 1